Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer Lines

Cellular signaling pathways involving mTOR, PI3K and ERK have dominated recent studies of breast cancer biology, and inhibitors of these pathways have formed a focus of numerous clinical trials. We have chosen trametinib, a drug targeting MEK in the ERK pathway, to address two questions. Firstly, do...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Euphemia Y., Kim, Ji Eun, Askarian-Amiri, Marjan, Rewcastle, Gordon W., Finlay, Graeme J., Baguley, Bruce C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149495/
https://www.ncbi.nlm.nih.gov/pubmed/25170609
http://dx.doi.org/10.1371/journal.pone.0105792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149495/
https://www.ncbi.nlm.nih.gov/pubmed/25170609
http://dx.doi.org/10.1371/journal.pone.0105792

Ejemplares similares